Full Press Release Details
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
San Diego, California / September 20, 2024 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.
"Our fiscal year 2024 was a transformational year for iBio, as we've solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics," said CEO and Chief Scientific Officer Martin Brenner, Ph.D., DVM. "We made significant progress entering the fast-growing cardiometabolic and obesity space with our collaboration with AstralBio and strengthened our financial position by eliminating our debt associated with the facility and closing a fully subscribed financing including participation from Ikarian Capital, Lynx1 Capital Management, ADAR1 Capital Management, and other institutional and accredited investors. We continued to build our drug discovery platform, adding innovative technologies that are helping to advance our pipeline and provide critical support to our biopharma partners with best-in-class antibody discovery and development projects."
Business Developments:
Corporate Developments:
"We ended this fiscal year well-positioned to advance our technology to drive value for patients and shareholders," said Chief Financial Officer Felipe Duran. "We strengthened our balance sheet through capital raises and debt extinguishment. In fiscal year 2024, we executed transactions which brought in non-dilutive funding, and we continue to pursue business development projects to strengthen our financial position."
Revenues for the fiscal year ended June 30, 2024, were approximately $0.2 million, an increase of 100% over fiscal 2023.
R&D and G&A expenses for fiscal 2024 decreased $5.1 million and $7.3 million, respectively, over the comparable period in fiscal 2023. The decrease in R&D and G&A reflects the Company's cost savings implemented to support its growing investments in its pipeline, platform technologies, employees, and related infrastructure.
iBio's consolidated net loss for the fiscal year ended June 30, 2024, was $24.9 million, a decreased loss of $40.1 million compared to 2023 primarily because of the decrease in expenses related to the Company's discontinued operations and cost saving initiatives.
iBio held cash, cash equivalents and restricted cash of $14.4 million as of June 30, 2024.
As disclosed in its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, which was filed on September 20, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its registered public accounting firm that includes an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 2 to the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Sections 401(h) and 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.
iBio is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers, and other diseases. iBio's mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements such as ending the fiscal year being well-positioned to advance the Company's technology to drive value for patients and shareholders; and continuing to pursue business development projects to strengthen the Company's financial position. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to successfully advance its technology and continue to pursue business development projects to strengthen the Company's financial position; its ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications; acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products; the continued maintenance and growth of its patent estate; its ability to establish and maintain collaborations and attract and increase partnership opportunities; competition; the substantial doubt exists related to the Company's ability to operate as a going concern; its ability to raise additional capital in order to fully execute the Company's longer-term business plans and the other factors discussed in the Company's filings with the SEC including the Company's Annual Report on Form 10-K for the year ended June 30, 2024. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
iBio, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(In Thousands, except per share amounts)
| Years Ended | ||||||
| June 30, | ||||||
| 2024 | 2023 | |||||
| Revenues | $ | 225 | $ | - | ||
| Operating expenses: | ||||||
| Research and development | 5,185 | 10,327 | ||||
| General and administrative | 11,674 | 19,016 | ||||
| Total operating expenses | 16,859 | 29,343 | ||||
| Operating loss | (16,634) | (29,343) | ||||
| Other income (expense): | ||||||
| Interest expense | (172) | (83) | ||||
| Interest income | 363 | 213 | ||||
| Loss on sales of debt securities | - | (98) | ||||
| Gain on sale of intellectual property | 1,000 | - | ||||
| Total other income | 1,191 | 32 | ||||
| Net loss from continuing operations | (15,443) | (29,311) | ||||
| Loss from discontinued operations | (9,464) | (35,699) | ||||
| Net loss | $ | (24,907) | $ | (65,010) | ||
| Comprehensive loss: | ||||||
| Consolidated net loss | $ | (24,907) | $ | (65,010) | ||
| Other comprehensive loss - unrealized gain on debt securities | - | 180 | ||||
| Other comprehensive income - foreign currency adjustment | - | 33 | ||||
| Comprehensive loss | $ | (24,907) | $ | (64,797) | ||
| Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - continuing operations | $ | (4.03) | $ | (47.88) | ||
| Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - discontinued operations | $ | (2.47) | $ | (58.31) | ||
| Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - total | $ | (6.50) | $ | (106.19) | ||
| Weighted-average common shares outstanding - basic and diluted | 3,831 | 612 |
iBio, Inc. and Subsidiaries
Consolidated Balance Sheets
(In Thousands, except share and per share amounts)
| June 30, 2024 | June 30, 2023 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 14,210 | $ | 4,301 | ||
| Restricted cash | - | 3,025 | ||||
| Subscription receivable | - | 204 | ||||
| Promissory note receivable and accrued interest | 713 | - | ||||
| Prepaid expenses and other current assets | 749 | 664 | ||||
| Current assets held for sale (see Note 3 - Discontinued Operations) | - | 18,065 | ||||
| Total Current Assets | 15,672 | 26,259 | ||||
| Restricted cash | 215 | 253 | ||||
| Promissory note receivable | 1,081 | 1,706 | ||||
| Finance lease right-of-use assets, net of accumulated amortization | 339 | 610 | ||||
| Operating lease right-of-use asset | 2,401 | 2,722 | ||||
| Fixed assets, net of accumulated depreciation | 3,632 | 4,219 | ||||
| Intangible assets, net of accumulated amortization | 5,368 | 5,388 | ||||
| Security deposits | 26 | 50 | ||||
| Total Assets | $ | 28,734 | $ | 41,207 | ||
| Liabilities and Stockholders' Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 358 | $ | 1,849 | ||
| Accrued expenses | 2,028 | 4,561 | ||||
| Finance lease obligations - current portion | 299 | 272 | ||||
| Operating lease obligation - current portion | 436 | 389 | ||||
| Equipment financing payable - current portion | 178 | 160 | ||||
| Term promissory note - current portion | 218 | - | ||||
| Insurance premium financing payable | 123 | - | ||||
| Term note payable - net of deferred financing costs | - | 12,937 | ||||
| Contract liabilities | 200 | - | ||||
| Current liabilities related to assets held for sale | - | 1,941 | ||||
| Total Current Liabilities | 3,840 | 22,109 | ||||
| Finance lease obligations - net of current portion | 53 | 351 | ||||
| Operating lease obligation - net of current portion | 2,688 | 3,125 | ||||
| Equipment financing payable - net of current portion | 63 | 241 | ||||
| Term promissory note - net of current portion | 766 | - | ||||
| Total Liabilities | 7,410 | 25,826 | ||||
| Stockholders' Equity | ||||||
| Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at June 30, 2024 and June 30, 2023; 0 shares issued and outstanding as of June 30, 2024 and June 30, 2023 | - | - | ||||
| Common stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2024 and June 30, 2023; 8,623,676 and 1,015,505 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively | 9 | 1 | ||||
| Additional paid-in capital | 335,162 | 304,320 | ||||
| Accumulated deficit | (313,847) | (288,940) | ||||
| Total Stockholders' Equity | 21,324 | 15,381 | ||||
| Total Equity | 21,324 | 15,381 | ||||
| Total Liabilities and Stockholders' Equity | $ | 28,734 | $ | 41,207 |